News Allergan ‘not looking for big deals’ as growth slows Company will put its $27 billion to use, however
News Merck, Allergan named as potential bidders for Biogen Biogen vulnerable to takeover as chief executive steps down
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
